There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates.
To bring these treatments to market, we need your help. The biggest obstacle in getting a celiac disease drug to market is recruiting enough patients to participate in clinical trials.
After years of fighting for our need for better treatments to be taken seriously, we now have companies interested in developing greatly needed treatments for celiac disease. We must follow through by showing up to participate in these studies.
The Celiac Disease Foundation is currently recruiting participants for three clinical trials in different phases (see below).
What Happens During Each Phase of a Clinical Trial?
In Phase 1, a new investigational drug is tested on a small group of people (approximately 20-100) to determine the drug’s safety.
In Phase 2, the investigational drug is tested on a larger group of people (approximately 100-300) to determine whether it has any effect on the disease.
In Phase 3, the investigational drug is tested on up to 3,000 people to determine its therapeutic effect compared to the current standard treatment for the disease.
Comparing Your Options
Each clinical trial is unique, with its own set of requirements for participant eligibility, travel, and time commitment.
To help you find the best fit, we put together a table comparing three clinical trials that are currently enrolling new participants: ACeD Study, PROACTIVE Celiac Study, and CeDLara study.
Click here to download the table.
|Study Sponsor||Anokion||Provention Bio||9 Meters Biopharma|
|Phase||Phase 1||Phase 2b||Phase 3|
|Approximate Length of Participation||Participants choose Group A or B
Group A: 7 weeks
Group B: 8 weeks
|36 weeks||30 weeks|
|Approximate Number of Study Site Visits||Group A: 5 visits
Group B: 6 visits
|17 visits||8 visits|
|Endoscopy with Biopsy||No||Yes||Optional|
|Medication Type||IV infusion||Injection||Oral capsule|
|Medication Description||Designed to create immune tolerance to gluten antigens by targeting the liver||Designed to block IL-15, a protein which triggers intestinal inflammation and damage in celiac patients||Designed to restore “leaky” junctions in the intestine to reduce inflammation caused by gluten|
|Chance of Receiving Placebo
|Group A: No placebo
Group B: 1 in 4
|1 in 4||1 in 3|
|Must be following a gluten-free diet to participate?||Yes, 12+ months||Yes, 12+ months||Yes, 6+ months|
|Must be actively experiencing celiac disease symptoms to participate?||No||Yes||Yes|
|Travel Reimbursement Available?||Yes||Yes||Yes|
|Study Site Locations||US||US & Canada||US & Canada|
|See If You Qualify||iqualify.celiac.org||survey.proactiveceliac.
See If You Qualify
Select a study below and fill out the brief screening survey to find out within minutes if you may qualify to participate:
Interested, but Have Questions or Concerns?
We understand feeling uncertain about participating in research, especially if you have never participated in a study before. We put together a list of some of the most common perceived barriers to participating in clinical trials and studies. We address each concern with information that we hope encourages you to consider participating.
Learn About Other Studies & Future Opportunities to Participate
Use our Clinical Trial Finder to search current registered trials by location.
Join iQualifyCeliac, our clinical study screening tool, to apply for open studies and find out within minutes if you may qualify to participate.
Join our iCureCeliac® patient registry to help accelerate celiac disease research, and be the first to hear about our new study opportunities.
Sign up for Celiac Disease Foundation email updates to stay informed on the latest studies, news, and more.
Which Clinical Trial Is Right for You?